Search for: "TEVA PHARMACEUTICALS v. ELI LILLY AND COMPANY "
Results 21 - 40
of 84
Sorted by Relevance
|
Sort by Date
9 Dec 2009, 3:59 pm
Teva Pharmaceuticals USA Inc. [read post]
7 Sep 2010, 6:10 pm
Highlights this week included: CAFC: Disclosure that merely allows PHOSITA to ‘envision’ the claimed invention fails written description: Goeddel v Sugano (Peter Zura’s 271 Patent Blog) (Patently-O) (Patent Prospector) Evista (Raloxifene) – US: CAFC upholds decision against Teva: Eli Lilly & Co v Teva Pharmaceuticals USA, Inc (Patent Docs) (The IP Factor) Aranesp (Darbepoetin) – EU: ECJ says… [read post]
10 Feb 2010, 4:47 pm
(Patent Docs) Doryx (Doxycycline) – US: Warner Chilcott files patent infringement suit against Sandoz in response to Para IV challenge (Patent Docs) Ebixa (Memantine) – Canada: Duty of good faith patent prosecution: Lundbeck v Ratiopharm (IP Osgoode) Focalin (Dexmethylphenidate) - US: Settlement announced in Focalin infringement dispute involving Celgene, Novartis Pharmaceuticals and Teva Pharmaceuticals (Patent Docs) Gemzar (Gemcitabine) – US:… [read post]
28 Nov 2008, 12:49 pm
victories in fight for European BRCA patents (Holman's Biotech IP Blog) Europe: European Commission proposes strategy for dealing with rare diseases (Pharmacapsules @ Gowlings) US: Former House Ways and Means Economist claims 7-year data exclusive period is sufficient (Patent Docs) US: Medco predicts follow-on biologics regulatory pathway by 2011 (Patent Docs) US: Even after patent has expired, District Court has jurisdiction to set exclusivity date: In re Omeprazole Patent Litigation… [read post]
24 Mar 2010, 4:45 am
Eli Lilly & Co. [read post]
24 Aug 2020, 12:00 am
In general, proceedings in the field of mechanical engineering will be classified as “regular” and proceedings in the field of pharmaceuticals as “complex”. [read post]
6 Jan 2010, 3:32 am
’ (The SPC Blog) India: Reviewing the Indian Patent Regime after 5 years of the introduction of the pharmaceutical product patent regime (Spicy IP) UK: Department of Health proposing generic prescription drugs option (GenericsWeb) US: 7th Circuit: Enforcing contracts between joint owners: Wisconsin Alumni Research Foundation (WARF) v. [read post]
16 Dec 2009, 3:39 am
Eli Lilly & Co. [read post]
18 Aug 2010, 12:19 am
(Patent Baristas) Strattera (Atomoxetine) – US: District Court rules against Lilly regarding Strattera patent: Eli Lilly v Actavis Elizabeth (GenericsWeb) Vigamox (Moxifloxacin) – US: Alcon denied permanent injunction against Teva in Vigamox litigation (Patent Docs) [read post]
12 Oct 2010, 8:56 pm
Highlights this week included: Aricept(Donepezil) –US: Declaratory judgment jurisdiction for subsequent Paragraph IV filers: Teva Pharmaceuticals USA, Inc. v. [read post]
28 Dec 2007, 1:00 am
: (IPBiz),Sinorgchem v. [read post]
10 Aug 2010, 8:44 pm
Highlights this week included: CAFC: Genus-species; doctrine of equivalents; and patentable subject matter: Intervet v Merial Limited (Patently-O) (Holman’s Biotech IP Blog) (IP Spotlight) (IPBiz) (Patent Docs) Angiomax (Bivalirudin) – US: The Medicines Company prevails in patent term extension dispute; USPTO acts quickly to comply with court order (Patent Docs) (Patent Docs) (IPBiz) Skelaxin (Metaxalone) – US: CAFC: Ignoring non-patentable elements while… [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb) General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
27 Feb 2009, 5:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Evista (Raloxifene) – US: CAFC affirms extension of 30-month stay against Teva’s generic Evista: Eli Lilly & Co v Teva Pharmas. [read post]
19 Dec 2008, 1:00 pm
$16.8 million for Alphapharm and Mylan: Takeda v Mylan (Patent Baristas) (Patent Docs) Boniva (Ibandronic acid) – US: Apotex challenges validity of Hoffmann-La Roche’s Boniva patent (Law360) Boniva (Ibandronic acid) – US: Orchid Chemicals & Pharmaceuticals and Orgenus Pharma seek declaratory judgment of invalidity and noninfringement in patent infringement suit brought by Hoffmann-La Roche over Boniva (Law360) Cardizem (Diltiazem) –… [read post]
28 Sep 2010, 3:14 pm
Eli Lilly & Co. [read post]
18 May 2011, 12:33 am
Highlights this week included: US: FTC alleges companies were asleep at the wheel when they failed to report settlement agreements on Ambien CR; Commission uses the opportunity to provide industry guidance – and a warning (FDA Law Blog) (GenericsWeb) Gemzar (Gemcitabine) – US: Certiorari denied in Eli Lilly v. [read post]
27 Apr 2010, 10:58 pm
Solstice International Partners et al (Docket Report) US: FTC annual report highlights the Commission’s patent settlement efforts (FDA Law Blog) Products Adcirca (Tadalafil) – US: Declaratory judgement of non-infringement and invalidity based on ANDA to manufacture generic Adcirca: Synthon v Eli Lilly et al (Patent Docs) Amrix (Cyclobenzaprine) – US: Mylan seeks declaratory judgment of noninfringement, unenforceability and invalidity of Amrix… [read post]
19 Apr 2010, 1:34 pm
The Federal Circuit has made it clear [in Eli Lilly & Co. v. [read post]
